Smith+Nephew names Sybella Stanley as new director

Published 01/14/2025, 02:05 AM
UK100
-
SN
-
SNN
-

LONDON - Smith+Nephew (LSE: SN, NYSE: SNN), the British multinational medical equipment manufacturing company, announced the appointment of Sybella Stanley as an independent Non-Executive Director, effective from February 1, 2025. The company, known for its advanced medical technology products, shared that Stanley will join its Board and is set to take over as Chair of the Remuneration Committee on June 30, 2025.

Stanley brings a wealth of experience to Smith+Nephew, having held the position of Director of Corporate Finance at RELX Plc since 1997. Her previous roles include serving as an Independent (LON:IOG) Non-Executive Director and Chair of the Remuneration Committee at Tate & Lyle (OTC:TATYY) plc, as well as at Merchants Trust PLC, where she also acted as Senior Independent Director. Stanley's retirement from these positions took place in December 2024 and March 2024, respectively. Additionally, she is a co-chair of the Development Board of Somerville College, Oxford.

Rupert Soames, Chair of Smith+Nephew, expressed his enthusiasm for the new addition to the Board, stating, "We are delighted to welcome Sybella to our Board. Her broad experience in successful global businesses in both senior management and non-executive capacities will further strengthen the Board." He also emphasized the company's commitment to strategic succession planning and the integration of diverse talents and expertise.

The appointment of Stanley is part of Smith+Nephew's ongoing efforts to enhance its governance and leadership capabilities. The company, which was founded in Hull, UK, in 1856, now operates in over 100 countries and generated annual sales of $5.5 billion in 2023. Smith+Nephew is included in the FTSE100 index and continues to focus on the development and provision of innovative medical technologies across its three global business units: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management.

Smith+Nephew has confirmed that no disclosure obligations arise under the UK Listing Authority's Listing Rules concerning Stanley's appointment. This announcement is based on a press release statement by Smith+Nephew.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.